Data from the RATIONALE 305 trial support the approval of tislelizumab/chemotherapy in unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.
Approval Alert | Tislelizumab/Chemotherapy in Gastric/GEJ Adenocarcinoma
Advertisement
Advertisement
Trending on CancerNetwork
1
How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?
2
HRQOL Finds Similar Responses Between Surgery/Treatment Options in NMIBC
3
Why Is Burden of Care the Biggest Challenge of Cancer Treatment?
4
The Paradigm of AML Care: What’s New and What’s Changing
5
